Comparative QSAR studies using HQSAR, CoMFA, and CoMSIA methods on cyclic sulfone hydroxyethylamines as BACE1 inhibitors

The inhibition of β-secretase (BACE1) is currently the main pharmacological strategy available for Alzheimer's disease (AD). 2D QSAR and 3D QSAR analysis on some cyclic sulfone hydroxyethylamines inhibitors against β-secretase (IC50: 0.002-2.75μM) were carried out using hologram QSAR (HQSAR), comparative molecular field analysis (CoMFA), and comparative molecular similarity indices analysis (CoMSIA) methods. The best model based on the training set was generated with a HQSAR q2 value of 0.693 and r2 value of 0.981; a CoMFA q2 value of 0.534 and r2 value of 0.913; and a CoMSIA q2 value of 0.512 and r2 value of 0.973. In order to gain further understand of the vital interactions between cyclic sulfone hydroxyethylamines and the protease, the analysis was performed by combining the CoMFA and CoMSIA field distributions with the active sites of the BACE1. The final QSAR models could be helpful in the design and development of novel active BACE1 inhibitors.

[1]  William P. Purcell,et al.  A brief review and table of semiempirical parameters used in the Hueckel molecular orbital method , 1967 .

[2]  Roger J.-B. Wets,et al.  Minimization by Random Search Techniques , 1981, Math. Oper. Res..

[3]  H. Kubinyi,et al.  3D QSAR in drug design. , 2002 .

[4]  Hyunah Choo,et al.  Comparative QSAR studies on peptide deformylase inhibitors , 2007, Journal of molecular modeling.

[5]  Kathryn Ziegler-Graham,et al.  Forecasting the global burden of Alzheimer’s disease , 2007, Alzheimer's & Dementia.

[6]  R. Cramer,et al.  Recent advances in comparative molecular field analysis (CoMFA). , 1989, Progress in clinical and biological research.

[7]  D. E. Patterson,et al.  Crossvalidation, Bootstrapping, and Partial Least Squares Compared with Multiple Regression in Conventional QSAR Studies , 1988 .

[8]  R. Cramer,et al.  Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. , 1988, Journal of the American Chemical Society.

[9]  Yu Chen,et al.  Evaluation of Quantitative Structure-Activity Relationship Methods for Large-Scale Prediction of Chemicals Binding to the Estrogen Receptor , 1998, J. Chem. Inf. Comput. Sci..

[10]  A. Henriques,et al.  Alkaloids as a source of potential anticholinesterase inhibitors for the treatment of Alzheimer's disease , 2013, The Journal of pharmacy and pharmacology.

[11]  Gerhard Klebe,et al.  Comparative Molecular Similarity Indices Analysis: CoMSIA , 1998 .

[12]  M. Staufenbiel,et al.  Discovery of cyclic sulfoxide hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure based design and in vivo reduction of amyloid β-peptides. , 2013, Bioorganic & medicinal chemistry letters.

[13]  S. Wold.  Cross-Validatory Estimation of the Number of Components in Factor and Principal Components Models , 1978 .

[14]  Bruce L. Bush,et al.  Sample-distance partial least squares: PLS optimized for many variables, with application to CoMFA , 1993, J. Comput. Aided Mol. Des..

[15]  G. Klebe,et al.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. , 1994, Journal of medicinal chemistry.

[16]  R. Cramer,et al.  Validation of the general purpose tripos 5.2 force field , 1989 .

[17]  R. Vassar,et al.  Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .

[18]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[19]  K. Kohn,et al.  Hydroxylated aromatic inhibitors of HIV-1 integrase. , 1995, Journal of medicinal chemistry.

[20]  P. Geladi.  Notes on the history and nature of partial least squares (PLS) modelling , 1988 .

[21]  R. Glennon.  Higher-End Serotonin Receptors: 5-HT5, 5-HT6, and 5-HT7 , 2003 .

[22]  Anne Corbett,et al.  Alzheimer's disease , 2011, The Lancet.

[23]  Jean-Michel Rondeau,et al.  Discovery of cyclic sulfone hydroxyethylamines as potent and selective β-site APP-cleaving enzyme 1 (BACE1) inhibitors: structure-based design and in vivo reduction of amyloid β-peptides. , 2012, Journal of medicinal chemistry.

[24]  S. Roggo.  Inhibition of BACE, a promising approach to Alzheimer's disease therapy. , 2002, Current topics in medicinal chemistry.

[25]  Johann Gasteiger,et al.  Multivariate structure‐activity relationships between data from a battery of biological tests and an ensemble of structure descriptors: The PLS method , 1984 .